Albendazole

證據等級: L5

預測適應症: 10 個

Albendazole: From Intestinal Helminthiasis to Alveolar Echinococcosis

One-Sentence Summary

Albendazole is a broad-spectrum benzimidazole anthelmintic, internationally approved for treating intestinal nematode infections including roundworm, hookworm, and whipworm, and included on the WHO Essential Medicines List. The TxGNN model predicts it may also be effective for Alveolar Echinococcosis, a life-threatening parasitic disease caused by Echinococcus multilocularis, with 5 clinical trials and 20 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Not registered in Singapore; internationally approved for intestinal nematode infections and echinococcosis
Predicted New Indication	Alveolar Echinococcosis
TxGNN Prediction Score	99.97%
Evidence Level	L2
Singapore Market Status	Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Based on published pharmacological literature, albendazole is metabolized in the liver to its primary active form, albendazole sulfoxide, which selectively inhibits β-tubulin polymerization in helminths. This disrupts the parasite's cytoskeleton, blocks intracellular glucose uptake, and ultimately leads to energy depletion and parasite death. Beyond this core antiparasitic mechanism, albendazole also exerts an anti-angiogenic effect by suppressing VEGF-driven cyst vascularization — a property particularly relevant to the infiltrative, tumour-like tissue invasion characteristic of alveolar echinococcosis.

Alveolar echinococcosis (AE) is caused by the metacestode larval stage of Echinococcus multilocularis, a tapeworm belonging to the same family of helminths that albendazole is established to combat. The mechanistic link is direct: albendazole's tubulin-inhibiting activity acts against the protoscoleces of E. multilocularis and exerts a parasitostatic effect that slows cyst expansion. This is not merely a class-effect extrapolation but a mechanistically grounded application of the drug's core pharmacology. Untreated AE approaches 100% case fatality within 10–15 years, making even parasitostatic therapy clinically significant.

The WHO Informal Working Group on Echinococcosis (WHO-IWGE) already formally lists albendazole as the first-line pharmacological treatment for AE, used either as sole therapy in inoperable cases or as adjuvant therapy alongside surgical resection. The TxGNN model's exceptional prediction score (99.97%) is therefore consistent with well-established real-world clinical use, supported by international guidelines and a growing body of clinical evidence.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT07182305	Phase 2	Completed	194	Treatment trial with Albendazole in early-stage alveolar echinococcosis (Kyrgyzstan); albendazole confirmed as effective parasitostatic agent; untreated AE has near-100% fatality within 10–15 years
NCT02876146	NA	Completed	50	EchinoVISTA prospective study: biological and imaging markers for monitoring hepatic AE patients on albendazole; aimed at defining criteria for safe treatment withdrawal
NCT06483880	NA	Unknown	24	RCT evaluating adjuvant albendazole vs placebo after pulmonary hydatid cyst resection to reduce 6-month recurrence; status unconfirmed
NCT05824442	NA	Recruiting	43	Diagnostic study evaluating multiplex qPCR for echinococcosis; albendazole described as the backbone of medical management but not the primary study intervention
NCT07176598	N/A	Completed	1	Case report of misdiagnosed primary intramuscular hydatid cyst; provides clinical phenomenology context only

Literature Evidence

PMID	Year	Type	Journal	Key Findings
19931502	2010	Expert Consensus Guideline	Acta Tropica	WHO-IWGE consensus: albendazole is first-line pharmacological treatment for both cystic and alveolar echinococcosis; covers diagnosis, treatment, and follow-up
30760475	2019	Systematic Review	Clinical Microbiology Reviews	Comprehensive 21st-century review of echinococcosis; albendazole remains the cornerstone of non-surgical AE management globally; discusses advances in genomics and diagnostics
39311470	2024	Review	Parasite (Paris)	Current state of chemotherapy for AE: benzimidazoles are the only WHO-recommended compounds; limitations include parasitostatic (not parasiticidal) action and hepatotoxicity risk with long-term use
36974024	2022	Review	Chinese J. Schistosomiasis Control	Progress of albendazole research for AE treatment; summarises formulation advances and combination strategies to overcome poor bioavailability
38501660	2024	Pharmacological Study	Antimicrobial Agents and Chemotherapy	Novel ABZ formulations (crystal dispersion, salt-polymer composites) developed to improve oral bioavailability; in vivo efficacy demonstrated in secondary hepatic AE rat models
25526545	2014	Review	Parasite (Paris)	Drug screening strategies for novel AE therapies; albendazole/mebendazole remain irreplaceable; outlines whole-organism screening approaches for new compounds
34808118	2022	Review	Acta Tropica	No licensed non-surgical alternative to albendazole/mebendazole currently exists for AE; urgent call for safer and more efficacious treatment options
40093668	2025	Review	World Journal of Gastroenterology	Albendazole combined with surgery is standard of care for hepatic echinococcosis; lifelong albendazole therapy recommended where complete resection is not achieved
39254012	2024	Review	Tidsskrift for den Norske Laegeforening	AE management requires extensive surgical resection plus prolonged albendazole use; cases increasingly imported into non-endemic regions including Norway
12667231	2003	Review	Fundamental & Clinical Pharmacology	Twenty-year review of albendazole in echinococcosis: established as an important component in management of both cystic and alveolar forms; chemotherapy alone sufficient in selected cases

Singapore Market Information

Albendazole is currently not registered in Singapore. No product authorization records are available in the Health Sciences Authority (HSA) database. Clinicians wishing to use this drug would need to apply through the HSA Special Access Route (SAR) for unregistered medicines.

Safety Considerations

Please refer to the package insert for safety information.

Note: Formal DrugBank safety data (warnings, contraindications, drug interactions) was not retrieved in this evidence cycle. Key safety signals known from literature include hepatotoxicity (requiring LFT monitoring), bone marrow suppression, and teratogenicity (contraindicated in pregnancy). A dedicated safety data pull is recommended before clinical use.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Albendazole is the WHO-recommended first-line pharmacological treatment for alveolar echinococcosis, supported by a completed Phase 2 clinical trial (n=194), multiple observational studies, expert consensus guidelines, and a mechanistically sound pharmacological basis. The TxGNN prediction score (99.97%) is consistent with this well-established clinical role.

To proceed, the following is needed:

Safety data retrieval: Download and parse the full prescribing information (package insert) to document key warnings, contraindications, and monitoring requirements — particularly hepatotoxicity, teratogenicity, and haematological suppression associated with long-term use
Drug interaction assessment: Complete a formal DDI review (current query returned no results), especially for patients on anticonvulsants, corticosteroids, or antiretrovirals
Singapore registration pathway: Evaluate the HSA Special Access Route (SAR) application process, given the absence of marketing approval in Singapore
Local supply sourcing: Identify importation or named-patient access pathways for albendazole procurement in Singapore
Monitoring protocol: Establish a structured treatment monitoring plan (LFTs, CBC with differential, renal function) appropriate for long-term AE therapy (typically ≥2 years of continuous treatment)
Radiological follow-up plan: Define imaging intervals (CT/MRI) to assess cyst response during albendazole therapy, aligned with WHO-IWGE staging criteria
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.